Skip to Content

Tag: Nasal high flow therapy

Lewis Gradon


F&P sees increased demand due to COVID-19 surges 

January 22, 2021HME News Staff

AUCKLAND, New Zealand – Fisher & Paykel Healthcare reports operating revenue for the nine months ended Dec. 31, 2020, was up 73% in constant currency compared to the prior comparable period.  In the hospital product group, operating revenue was up 113%, with hardware growing 446% and consumables growing 54%.  “In many parts of the world, we have continued to see an influx of COVID-19 patients requiring hospitalization for respiratory treatment,” said Lewis Gradon,...

Coronavirus, Financial Results, Fisher & Paykel Healthcare, Nasal high flow therapy, Obstructive Sleep Apnea (OSA), Pandemic, Sleep Therapy

Read Full Articlered right arrow icon